A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Breast Cancer Clinical Trial

— PALLET  

Official title:

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02296801
• Other study ID #: NSABP FB-11
• Secondary ID: WI180455
• Status: Completed
• Phase: Phase 2
• Start date: January 2015
• Est. completion date: March 2019

Study information

• Verified date: December 2021
• Source: NSABP Foundation Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated. Letrozole is a type of endocrine therapy called an aromatase inhibitor (AI) and is standard treatment for post-menopausal women with ER-positive/HER2-negative breast cancer.

Description:

The FB-11 study is a Phase II, randomized, open label, four arm study to examine the biological and clinical effect of neoadjuvant letrozole with or without palbociclib in the first-line treatment of estrogen-receptor (ER) positive, HER2-negative early invasive breast cancer. The co-primary aims of this study are to to compare the changes in the proliferation marker Ki67, and to compare clinical response after 14 weeks of therapy with letrozole with or without palbociclib. The FB-11 study initiative is a joint partnership between the NSABP Foundation, Inc. (NSABP) Department of Site and Study Management (DSSM) and United Kingdom (UK) co-investigators at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (ICR). Parallel protocols will be conducted in the US and Canada (FB-11), and the UK (PALLET) with joint analysis of interim and final data. Postmenopausal women, newly diagnosed with ER-positive/HER2-negative early breast cancer, who are suitable candidates for neoadjuvant endocrine therapy will be invited to join the FB-11/PALLET trial. Approximately 306 patients will be accrued to this study. Each collaborative group will recruit at least 1/3 and no more than 2/3 of the target accrual. Patients will be randomized to one of four treatment arms (3:2:2:2 ratio). Treatment in the first 14 weeks of neoadjuvant therapy will be:Arm A Letrozole alone; Arm B Letrozole for 2 weeks followed by letrozole + palbociclib to week 14; Arm C Palbociclib for 2 weeks followed by letrozole + palbociclib to week 14; Arm D Letrozole + palbociclib to week 14. Letrozole will be administered orally as a 2.5mg daily tablet. Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week [28 day] cycle. The end of study therapy for patients in Arm A will be completion of week 14. Patients in Arms B, C, and D will complete study therapy following 14 days of palbociclib in the final treatment cycle past 14 weeks if treatment delays have occurred. Note: After week 14 (end of study therapy) all patients should continue letrozole until surgery. Letrozole is not considered study therapy beyond completion of week 14 for Arm A or after 14 days of palbociclib in the final treatment cycle for patients in Arms B, C, and D. Following completion of study therapy, surgery will be scheduled for 15-18 weeks post-randomization. Post-surgical treatment will be at discretion of treating clinician, following local protocols, and not influenced by allocation of treatment within the FB-11/PALLET study. Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 307
• Est. completion date: March 2019
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be postmenopausal women defined as: Age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or Age 55 or younger with no menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or Age greater than or equal to 18 with documented bilateral oophorectomy.
• Operable ER-positive/HER2- negative, invasive early breast cancer, suitable for neoadjuvant AI treatment. HER2-negative as determined by American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines.
• No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.
• A breast tumor with an ultrasound size of at least 2.0 cm.
• Patients must have the ability to swallow oral medication.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• At the time of randomization, blood counts performed within 4 weeks prior to randomization must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL.
• international normalized ratio (INR) must be within normal limits of the local laboratory ranges.
• The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to study entry must be met: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be must be less than or equal to 1.5 x ULN for the lab; and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab.
• Serum creatinine performed within 4 weeks prior to study entry must be less than or equal to 1.25 x ULN or estimated creatinine clearance less than 60 mL/min (as calculated using the method standard for the institutions).

Exclusion Criteria:

• Active hepatitis B or hepatitis C with abnormal liver function tests.
• HIV positive patients receiving antivirals.
• Premenopausal or peri-menopausal women.
• Inflammatory/inoperable breast cancer.
• HER2-positive as determined using ASCO-CAP Guidelines.
• Concurrent use (defined as use within 4 weeks prior to baseline tissue sample being taken) of hormone replacement therapy (HRT) or any other estrogen-containing medication (including vaginal estrogens)
• Prior endocrine therapy for breast cancer.
• Any invasive malignancy within previous 5 years (other than basal cell carcinoma or cervical carcinoma in situ).
• Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up such as: Active infection or chronic infection requiring chronic suppressive antibiotics; Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting gastrointestinal function; Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids); Seizure disorders requiring medication.
• Diagnosis by fine needle aspiration (FNA) alone or excisional biopsy or lumpectomy performed prior to study entry.
• Surgical axillary staging procedure prior to study procedure (with exception of FNA or core biopsy).
• Definitive clinical or radiologic evidence of metastatic disease.
• History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in situ (DCIS) treated with radiotherapy or contralateral invasive breast cancer at any time.
• Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.
• Use of any medication or substances that are strong inhibitors or inducers of CYP3A isoenzymes.
• Class III or Class IV myocardial disease as described by the New York Heart Association; a recent history (within 6 months) of myocardial infarction, or symptomatic arrhythmia at the time of randomization. Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Such patients are comfortable at rest. Less than ordinary physical activity that causes fatigue, palpitation, dyspnea, or anginal pain. Class IV: Patients with cardiac disease resulting in inability to perform any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest.
• QTc greater than 480 msec or a family or personal history of long or short QT syndrome, Brugada syndrome or know history of QTc prolongation, or Torsade de Pointes (TdP).
• The investigator should assess the patient to determine if she has any psychiatric or addictive disorder or other condition that, in the opinion of the investigator, would preclude her from meeting the study requirements.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Carcinoma
• Breast Neoplasms
• Breast Tumors

Intervention

Drug:
• Letrozole

• palbociclib

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Universite de Montreal	Montreal	Quebec
Canada	Jewish General Hospital	Montreal	Quebec
Canada	McGill University Health Center	Montreal	Quebec
Canada	CHU de Quebec - Universite Laval	Quebec City	Quebec
United Kingdom	Belfast City Hospital	Belfast
United Kingdom	Royal Bournemouth Hospital	Bournemouth
United Kingdom	Royal Sussex County Hospital	Brighton	East Sussex
United Kingdom	Darent Valley Hospital	Dartford	Kent
United Kingdom	Western General Hospital (Edinburgh Cancer Centre)	Edinburgh
United Kingdom	Royal Devon and Exeter Hospital	Exeter	Devon
United Kingdom	James Paget University Hospital	Great Yarmouth	Norfolk
United Kingdom	Hinchingbrooke Hospital	Huntingdon	Cambridgeshire
United Kingdom	Kidderminster Hospital	Kidderminster	Worcestershire
United Kingdom	St James' University Hospital	Leeds
United Kingdom	Royal Liverpool University Hospital	Liverpool	Merseyside
United Kingdom	Barnet Hospital	London
United Kingdom	Charing Cross Hospital	London
United Kingdom	The Royal Marsden Hospital	London
United Kingdom	University College London Hospitals	London
United Kingdom	Whittington Hospital	London
United Kingdom	Maidstone Hospital	Maidstone	Kent
United Kingdom	Milton Keynes Hospital	Milton Keynes	Buckinghamshire
United Kingdom	Nottingham University Hospitals NHS Trust, City Campus	Nottingham
United Kingdom	Derriford Hospital	Plymouth
United Kingdom	Alexandra Hospital	Redditch	Worcestershire
United Kingdom	Salisbury Hospital	Salisbury	Wiltshire
United Kingdom	The Royal Marsden Hospital	Sutton	Surrey
United Kingdom	Singleton Hospital	Swansea
United Kingdom	Musgrove Park Hospital	Taunton	Somerset
United Kingdom	Royal Cornwall Hospital, Treliske	Truro	Cornwall
United Kingdom	Southend Hospital	Westcliff-on-Sea	Essex
United Kingdom	Weston General Hospital	Weston-Super-Mare	Somerset
United Kingdom	Worcestershire Royal Hospital	Worcester	Worcestershire
United States	Hope Women's Cancer Centers	Asheville	North Carolina
United States	Sentara Martha Jefferson Hospital-Phillips Family Cancer Center	Charlottesville	Virginia
United States	Cancer Care Specialists of Central Illinois	Decatur	Illinois
United States	Baylor College of Medicine	Houston	Texas
United States	Long Beach Memorial Medical Center-Todd Cancer Institute	Long Beach	California
United States	Norton Cancer Institute - Brownsboro Medical Plaza I	Louisville	Kentucky
United States	Norton Cancer Institute - Suburban, Norton Medical Plaza II	Louisville	Kentucky
United States	Norton Healthcare Pavillion	Louisville	Kentucky
United States	Joe Arrington Cancer Research and Treatment Center	Lubbock	Texas
United States	Pinnacle Health Ortenzio Cancer Center	Mechanicsburg	Pennsylvania
United States	University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center	Miami	Florida
United States	West Virginia University	Morgantown	West Virginia
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Providence Oncology and Hematology Clinic	Portland	Oregon
United States	Women and Infants Hospital of Rhode Island	Providence	Rhode Island
United States	Virginia Commonwealth University	Richmond	Virginia
United States	Metro-Minnesota CCOP	Saint Louis Park	Minnesota
United States	Swedish Cancer Institute	Seattle	Washington

Sponsors (4)

Lead Sponsor	Collaborator
NSABP Foundation Inc	Institute of Cancer Research, United Kingdom, Pfizer, Royal Marsden NHS Foundation Trust

Countries where clinical trial is conducted

United States,  Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the Proliferation Marker Ki67 (% Positive Tumor Cells)	The change in Ki67 from baseline to 14 weeks.	Baseline and at 14 weeks
Primary	Clinical Response : Number of Patients Who Have Resolution of Measurable Lesions or no New Lesions or Other Signs of Disease Progression Compared to Baseline.	Clinical Response is assessed by ultrasound at the end of the treatment (week 14) according to ECOG response criteria defined in Appendix A1 of the protocol. Number of participants with clinical complete response.	Baseline and at 14 weeks
Secondary	Pathological Complete Response (pCR): Number of Patients With no Lesions in Breast and Nodes at Time of Surgery	Pathologic complete response in the breast (pCR breast) is defined as no histologic evidence of invasive tumour cells in the surgical breast specimen. Pathologic complete response in breast and axillary lymph nodes as well as non-axillary SN (pCR breast & nodes) is defined as no histologic evidence of invasive tumour cells in the surgical breast specimen, axillary nodes, or SNs identified after neoadjuvant treatment. Data shows the pCR rates by randomised group.	14 weeks
Secondary	Preoperative Endocrine Prognostic Index (PEPI) Score:	The PEPI score estimates the risk of cancer recurrence after treatment. Analysis of the PEPI score were pre-specified in the protocol and statistical analysis plan. However, pathological/biomarker characteristics which comprise this score such as the Allred score for ER status were not collected during the trial so cannot be calculated at this stage. PEPI Scale range is 0-16 for RFS. Higher score represents worse outcome. No combination of subscales.	14 weeks
Secondary	Number and Severity of Adverse Events	To evaluate the overall safety and tolerability for the combination of letrozole and palbociclib. The number of patients experiencing at least one adverse event. Refer to Adverse Events section for more details.	Baseline and weekly through 12 months after randomization
Secondary	Measurement of Ki67 Marker	To compare Ki67 results after 2 weeks and 14 weeks of study therapy. Log fold change in Ki67 from week 2-week 14.	Week 2 and week 14
Secondary	Comparison of Surgical Intent (Mastectomy; Breast Conservation)	To compare changes between surgical intent at baseline; surgical intent after 14 weeks; and actual surgery received after treatment with letrozole with or without palbociclib. Percentage of patients change to receiving breast conservation and receiving breast conservation.	Time frame between baseline and surgery date. (Note-surgical intent happened before randomization).